Powered by LawFuel – January 23, 2020 – DLA Piper announced today that Christopher Mikson has joined the firm’s Litigation practice as a partner in Philadelphia and Washington, DC.
Mikson, who is also a medical doctor and registered patent attorney, is an accomplished litigator who focuses on Food and Drug Administration regulatory matters; complex intellectual property, commercial and product liability litigation; and transactional due diligence and counseling in the healthcare and life sciences industries.
“Chris’s unique training as a physician and lawyer makes him an invaluable addition to our growing life sciences practice,” said Loren Brown, global and US co-chair of DLA Piper’s Litigation practice. “He will greatly enhance both our regulatory and litigation capabilities in this key sector, and we are confident that our clients will value his advice and counsel immediately.”
“Chris is a great fit for our platform, and he brings a skillset that adds depth to our capabilities in a number of areas, including FDA regulatory, product liability and intellectual property matters,” said Jeff Lehrer, managing partner of the firm’s Washington, DC, office. “We are thrilled to welcome him on board.”
Mikson, who joins from Mayer Brown, received his J.D. from Rutgers Law School and his B.A. from Rutgers College. He completed the Post-Baccalaureate Premedical Program at the University of Pennsylvania and received his M.D. from Jefferson Medical College.
Recent Posts on LawFuel
- Linklaters Smashes Record as Aggressive US Expansion Pushes to Unprecedented FY26 Heights
- Freshfields Cut Its European Partners. Its New York Partners Got A Raise.Freshfields’ US growth ambitions has forced out equity partners across London, Paris and Germany, the Financial Times reported on 13 July, weeks after a pay overhaul left dozens of its roughly 500 partners holding fewer equity points. Freshfields reset its internal exchange rate from $1.60 to the pound down to about $1.30, then handed extra points to its top US earners so their dollar pay held. Points are a share of a fixed pool and Freshfields’ European partners are the pool. The Financial Times reported this week that Freshfields has culled equity partners in recent weeks, with its London headquarters and its Paris and German offices all seeing exits and equity downgrades. City AM ran it as a shake-up to fund the American push, which it is. What neither write-up reached is the ledger entry that explains it, and that ledger entry has been sitting in public since March. Log in to read . . .
- The Judge’s Brutal Verdict on the Lawyering Behind Harry’s £50m Mail Disaster
- How Trump Turned Big Law Lobbying Into A Billion‑Dollar Profit EngineWhen Donald Trump turned Washington into a rolling policy experiment, most law firms braced for chaos, but a handful quietly built something else: – a brand new profit engine. Lobbying and government‑relations work, once treated as a sideline for politically connected partners, has become one of Big Law’s fastest‑growing business and a new career path for lawyers from DC to Westminster The Trump‑Era Shock For decades, lobbying has sat on the fringes of large law firms and what they traditionally do. There were always a few partners with good contacts, intermittent mandates, and work that was important but they were rarely central to the firm’s story and what the firm really ‘did’. Log in to read . . .
- What Does the KPMG Scandal Means for Law Firms and Internal Investigations
- Kennedy’s Report 12th Year of Growth As The Firm Moves Towards Its $1 Billion Target
- The OpenAI Defense: Inside the Wachtell Trial Team That Just Beat Elon MuskWhile Elon Musk’s legal team tried to transform a federal courtroom in Oakland, California into an existential debate about the fate of human civilization and a “stolen charity,” Sam Altman’s defenders quietly built a procedural guillotine. A unanimous nine-member federal advisory jury took less than two hours to reject all of Musk’s claims against OpenAI, CEO Sam Altman, and President Greg Brockman, which presumably was both surprising and disappointing for the multi-billionaire. U.S. District Judge Yvonne Gonzalez Rogers immediately adopted the verdict from the bench, dismissing the case in full. The same statute-of-limitations finding wiped out Musk’s aiding-and-abetting claim against Microsoft, an early backer of OpenAI’s for-profit arm. Log in to the the lawyer profiles . . .
- The $8 Billion Fight That Shows Why Litigation Is Still the City’s Ultimate Blood SportA monster battle is unfolding in the sprawling claim against audit powerhouse PwC, born from the spectacular implosion of Chinese property behemoth China Evergrande, the most indebted property group in the world. Senior silks like Richard Handyside KC, the Fountain Court Chambers’ Head, are facing off against those from 3 Verulam Buildings (3VB) where Adrian Beltrami KC represents the liquidators as they battle over allegations of negligence and misrepresentation in the $8.4 billion battle. The numbers are eye-watering, even by City standards. Evergrande’s liquidators (led by Alvarez & Marsal’s Edward Middleton and Tiffany Wong) are pursuing 57 billion yuan (roughly $8.4 billion) in damages from PwC International, PwC Hong Kong, and PwC’s mainland China arm. They allege serious audit negligence and misrepresentation in the years leading up to Evergrande’s historic collapse, a King-sized property failure in a long list of major property failures. Log in to read more . . .
- Paul Weiss Loses Two More Litigation Partners As Rivals Keep Picking Off Its Bench
